David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Scholar Rock Holding Corp (SRRK), with a market capitalization of nearly $3 billion, released its Q1 2025 earnings, reporting an... By Investing.com • May 14, 2025 ...

A high-level overview of Scholar Rock Holding Corporation (SRRK) stock. View (SRRK) real-time stock price, chart, news, analysis, analyst reviews and more.

Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

After more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down as CEO, to be replaced by biopharma industry veteran Tony Kingsley. Mahanthappa will stay on ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

View the latest Scholar Rock Holding Corp. (SRRK) stock price, news, historical charts, analyst ratings and financial information from WSJ.